Risankizumab Drug Aliquot | Anti-IL23 | Therapeutic Antibody

Aliquoted from the original reference drug | Now available for research use

Aliquots of the reference drug Risankizumab are now available as research consumables.

Risankizumab drug aliquots can be used for in vitro or in vivo experiments. For biosimilar development, different batches of Risankizumab drug can be ordered at the same time. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Risankizumab Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Skyrizi® / Risankizumab Reference Product

Drug nameSkyrizi®
INNRisankizumab
API typeRisankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody selective to the interleukin (IL)-23 protein produced in Chinese Hamster Ovary cells using recombinant DNA technology.
Pharmacotherapeutic group
Immunosuppressants, interleukin inhibitors.
ATC code
L04AC18
Target of antibody
IL-23
General functionRisankizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds with high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine without binding to IL-12 and inhibits its interaction with the IL-23 receptor complex. IL-23 is a cytokine that is involved in inflammatory and immune responses. By blocking IL-23 from binding to its receptor, risankizumab inhibits IL-23-dependent cell signalling and release of proinflammatory cytokines.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)In a study of subjects with psoriasis, expression of genes associated with the IL-23/IL-17 axis was decreased in the skin after single doses of risankizumab. Reductions in epidermal thickness, infiltration of inflammatory cells, and expression of psoriatic disease markers were also observed in psoriatic lesions.
Original license holder
AbbVie Biotechnology GmbH
Knollstrasse
67061 Ludwigshafen
Germany
Marketing authorisation numbers
EU/1/19/1361/001
Marketing authorisation holder
AbbVie Deutschland GmbH & Co. KG
Knollstrasse
67061 Ludwigshafen
Germany
Name of the manufacturer of the biological active substance
Boehringer Ingelheim Pharma GmbH & Co. KG
Birkendorfer Str. 65
88397 Biberach a.d.R.
GERMANY
and
AbbVie Bioresearch Center Inc.
100 Research Drive
Worcester
MA 01605
USA
Name and address of the manufacturer(s) responsible for batch releaseAbbVie S.r.l.
148, Pontina Km 52 snc
04011
Campoverde di Aprilia (LT)
ITALY
and
AbbVie Deutschland GmbH & Co. KG
Knollstrasse
67061 Ludwigshafen
GERMANY
Max shelf life
24 months
Storage conditions
2°C – 8°C
List of excipients
Disodium succinate hexahydrate
Succinic acid
Sorbitol
Polysorbate 20
Water for injections

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

we are recruiting